Pacira Pharmaceuticals Stock News

RBC Capital analyst Randall Stanicky maintained a Hold rating on Merck & Company (MRK) today and set a price target of $89.00. The company's shares

RBC Capital analyst Randall Stanicky maintained a Hold rating on Merck & Company ( MRK – Research Report ) today and set a price target of $89.00 . The company’s shares closed last Monday at $76.9

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Danaher (DHR), Amneal Pharmaceuticals (AMRX) and CytomX

Envestnet Asset Management Inc. purchased a new position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Co

In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Hold rating on Amarin (AMRN), with a price target of $8.00. The company's

In a report issued on March 27, Randall Stanicky from RBC Capital maintained a Buy rating on Perrigo Company (PRGO), with a price target of $58.00. The

In a report issued on March 27, Randall Stanicky from RBC Capital maintained a Buy rating on Perrigo Company (PRGO

Pacira Biosciences (NASDAQ:PCRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday, Zacks.com reports. They presently h

Pacira Biosciences Inc (NASDAQ:PCRX) was the recipient of some unusual options trading activity on Friday. Stock investors bought 4,061 call options on the stock. This is an increase of 1,931% compare

In a report released today, Randall Stanicky from RBC Capital maintained a Buy rating on Mylan (MYL), with a price target of $26.00. The company's shares

In a report released today, Randall Stanicky from RBC Capital maintained a Buy rating on Mylan (MYL – Research Report),

In a report released today, Randall Stanicky from RBC Capital maintained a Buy rating on Pfizer (PFE), with a price target of $44.00. The company's shares

In a report released today, Randall Stanicky from RBC Capital maintained a Buy rating on Pfizer ( PFE – Research Report ), with a price target of $44.00 . The company’s shares closed last Monday a

Pacira Biosciences Inc (NASDAQ:PCRX)’s share price traded up 4.2% during mid-day trading on Wednesday . The stock traded as high as $31.99 and last traded at $31.53, 20,670 shares were traded during

Equities analysts predict that Pacira Biosciences Inc (NASDAQ:PCRX) will report sales of $109.62 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimate